Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Horizon and Promega Launch Suite of X-MAN Reporter Kits

Published: Monday, March 11, 2013
Last Updated: Monday, March 11, 2013
Bookmark and Share
New kits enable the study of protein characteristics and behaviors at endogenous expression levels.

Horizon Discovery Ltd. (Horizon) and Promega Corporation have announced the launch of a suite of X-MAN™ Reporter Kits. These kits enable researchers, for the first time, to apply functional, cell-based assays that directly interrogate critical biological activities, at endogenous expression levels.

The resulting data is therefore a closer representation of biological disease states.

The X-MAN Reporter Kits are designed for investigation of: protein expression levels, protein localization within a cell, and protein-protein interaction within a molecular pathway, at natural levels of protein and promoter activity.

The kits include genetically-defined reporter cell lines generated using Horizon’s proprietary GENESIS™ gene editing technology with Promega’s innovative and market-leading luminescent and fluorescent reporter technologies.

X-MAN NanoLuc™ Reporter cell lines incorporate Promega’s new NanoLuc Luciferase reporter directly into the native loci of genes of interest, permitting evaluation of genes and proteins at physiologically relevant levels. NanoLuc is the smallest and brightest luciferase reporter available.

X-MAN HaloTag® Reporter cell lines facilitate the introduction of Promega’s HaloTag as an N- or C-terminal fusion to genes encoding proteins of interest at their native genetic loci.

By using different ligands that bind to HaloTag, these cell lines can then be used to look directly at protein localization at endogenous levels including in live cells or to perform protein interaction studies and to capture the protein of interest for further investigation.

Horizon and Promega have also developed X-MAN Glo™ Reporter Kits, which include X-MAN cell lines pre-transfected with Promega’s Firefly Luciferase for in vivo imaging and VivoGlo™ luciferin, provided as isogenic cell lines for experimental control.

These kits enable in vitro experiments to be linked to in vivo imaging through a common parental/mutant cell line pair, leading to improved continuity of findings.

Dr. Paul Morrill, Vice President, Products, Horizon Discovery, said: “Combining Horizon’s X-MAN and GENESIS technologies with Promega’s market-leading reporters has enabled us to create a powerful new suite of tools that allow investigators to study protein expression, interactions, and encoding, at endogenous expression levels. The resulting data sets are more reflective of the biological disease states versus an artefact of the model itself.”

Tom Livelli, Vice President Life Sciences Products and Services, Promega Corporation, commented: “Promega identified Horizon’s GENESIS gene editing technology and X-MAN cell lines as pioneering translational genomics and drug discovery platforms and began working with the Company in 2011. Combined with our world-leading reporter technology, we have created a suite of invaluable tools for the investigation of genetic disease, and the development of new, targeted therapies.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Horizon Enters Bioproduction Cell Line Licensing Agreement with LakePharma, Inc.
LakePharma to take a full commercial license for GS null CHO K1 cell line from Horizon for improved efficiency in biopharmaceutical manufacturing.
Wednesday, September 16, 2015
Horizon and Redx Sign Cancer Research Collaboration
Collaboration to progress Redx Pharma plc’s novel pan-RAF inhibitor program towards out-licensing.
Friday, September 04, 2015
Horizon Discovery Appoints Mr Grahame Cook as a Non-Executive Director
Grahame brings over 20 years’ experience to Horizon.
Thursday, May 14, 2015
Transgenomic to Incorporate Horizon's Genomic Reference Standards
Horizon to provide human genomic reference standards to assure quality and performance of Transgenomic’s Multiplexed ICE COLD-PCR kits.
Thursday, April 23, 2015
Horizon Discovery & Thermo Agreement
Horizon Discovery Group plc and Thermo Fisher Scientific sign supply and commercialization agreement, which will see Thermo market and distribute Horizon’s X-MAN cell line collection.
Monday, April 20, 2015
Horizon and Partners Awarded Up to £6.2M Funding
Horizon to receive up to £652,000 to expand bioproduction research.
Thursday, March 26, 2015
Horizon Discovery Group plc and ArcherDX Sign OEM Agreement
Horizon’s Reference Materials chosen by ArcherDX to validate its FusionPlex test for non-small cell lung cancer markers.
Tuesday, March 24, 2015
Horizon Discovery Group plc Named Business of the Year at Business Weekly Awards
Horizon joins select group of companies to receive award for a second time.
Wednesday, March 18, 2015
Horizon to Support Cancer Research UK’s Stratified Medicine Program
Horizon’s Diagnostics division to provide genetically defined, human genomic reference standards.
Friday, March 13, 2015
Horizon Discovery Group to Support Cancer Research UK’s Stratified Medicine Program
Horizon’s Diagnostics division to provide genetically defined, human genomic reference standards.
Wednesday, March 11, 2015
Horizon Discovery CEO Darrin Disley wins Entrepreneur of the Year
Darrin Disley, CEO of Horizon Discovery, wins Entrepreneur of the Year award at the Quoted Company Awards 2015.
Thursday, January 29, 2015
Horizon Discovery Group plc Trading Update
Revenues expected to be ahead of consensus by approximately 7% driven by an increased global demand for expanded product, service and IP offering.
Monday, January 19, 2015
Horizon Discovery Group plc Acquires Haplogen Genomics GmbH
Strategic acquisition of high-throughput functional genomics platform aims to drive product development, revenue growth and enable broader market penetration.
Thursday, January 08, 2015
Horizon Discovery CEO Wins Executive of the Year
Darrin Disley wins Executive of the Year award at the SCRIP Awards.
Thursday, December 04, 2014
Horizon Discovery Group Signs Agreement with Top Ten Pharma Company for Approximately $750,000
Horizon CombinatoRx to perform drug combination screening on a lead oncology asset.
Monday, November 17, 2014
Scientific News
Lung Repair and Regeneration Gene Discovered
New role for hedgehog gene offers better understanding of lung disease.
3 Ways Viruses Have Changed Science for the Better
Viruses are really good at what they do, and we’ve been able to harness their skills to learn about – and potentially improve – human health in several ways.
Mixed Up Cell Transportation Key Piece of ALS and Dementia Puzzle
Researchers from the University of Toronto are one step closer to solving this incredibly complex puzzle, offering hope for treatment.
New Gene Therapy for Vision Loss From a Mitochondrial Disease
NIH-funded study shows success in targeting mitochondrial DNA in mice.
Five New Genetic Variants Linked to Brain Cancer Identified
The biggest ever study of DNA from people with glioma – the most common form of brain cancer – has discovered five new genetic variants associated with the disease.
Predictive Model for Breast Cancer Progression
Biomedical engineers have demonstrated a proof-of-principle technique that could give women and their oncologists more personalized information to help them choose options for treating breast cancer.
Fatty Liver Disease and Scarring Have Strong Genetic Component
Researchers say that hepatic fibrosis, which involves scarring of the liver that can result in dysfunction and, in severe cases, cirrhosis and cancer, may be as much a consequence of genetics as environmental factors.
Specific Variations in RNA Splicing Linked to Breast Cancer
Researchers have identified cellular changes that may play a role in converting normal breast cells into tumors. Targeting these changes could potentially lead to therapies for some forms of breast cancer.
Finding Links and Missing Genes
A catalogue of large-scale genetic changes around the world.
Scientists Test New Gene Therapy for Vision Loss from a Mitochondrial Disease
NIH-funded study shows success in targeting mitochondrial DNA in mice.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos